Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of OX118 in Healthy Volunteers
NCT07020156Phase 1Recruiting
- Sponsor
- Oxion Biologics
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OX118 in Inflammatory Disorders and Rheumatic diseases (5 cohorts), sponsored by Oxion Biologics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Number of Participants with Abnormal Vital Signs and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
OX118
03
Conditions
Inflammatory DisordersRheumatic diseases
Beyond the preview
Go deeper on NCT07020156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020156.